51 recruiting. 51 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 51 | Recruiting 51 |
| Phase 2 | 9 | Recruiting 9 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Ponesimod, Placebo - Ulcerative Colitis (UC) | Phase 3 | Recruiting | Vanda Pharmaceuticals | 150 | 2026-09-01 | 2026-08-18 |
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) Modafinil, Placebo - Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Chronic Fatigue | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 60 | 2026-08-03 | 2026-09-14 |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis JNJ-78934804, Guselkumab - Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 644 | 2026-05-23 | 2026-10-13 |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease JNJ-78934804, Guselkumab - Crohn Disease | Phase 3 | Recruiting | Janssen Research & Development, LLC | 460 | 2026-05-22 | 2026-10-14 |
| Vancomycin Taper to Prevent Recurrent Clostridioides Difficile Fidaxomicin, Vancomycin capsule - Clostridia Difficile Colitis | Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 500 | 2026-04-24 | 2026-09-23 |
| A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Guselkumab, Risankizumab - Crohn Disease | Phase 3 | Recruiting | Janssen Research & Development, LLC | 530 | 2026-04-21 | 2026-09-25 |
| Holy Basil in The Treatment of Dyspepsia Holy basil extract - Dyspepsia and Other Specified Disorders of Function of Stomach | Phase 2 / Phase 3 | Recruiting | Mahidol University | 27 | 2026-02-13 | 2026-03-24 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease Duvakitug, Placebo - Crohn's Disease | Phase 3 | Recruiting | Sanofi | 751 | 2026-01-22 | 2026-10-21 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Duvakitug, Placebo - Ulcerative Colitis | Phase 3 | Recruiting | Sanofi | 751 | 2026-01-16 | 2026-10-16 |
| A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis dupilumab - Eosinophilic Esophagitis (EoE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 20 | 2025-11-10 | 2026-09-29 |
| A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) Vedolizumab SC, No Intervention - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-10-27 | 2026-10-09 |
| An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Duvakitug, Placebo - Ulcerative Colitis | Phase 3 | Recruiting | Sanofi | 980 | 2025-10-08 | 2026-10-23 |
| A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease Icotrokinra, Placebo - Crohn Disease | Phase 2 / Phase 3 | Recruiting | Janssen Research & Development, LLC | 1092 | 2025-10-03 | 2026-09-25 |
| A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis Icotrokinra, Placebo - Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 882 | 2025-10-01 | 2026-09-25 |
| An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease Duvakitug, Placebo - Crohn's Disease | Phase 3 | Recruiting | Sanofi | 980 | 2025-10-01 | 2026-10-21 |
| A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis Filgotinib - Ulcerative Colitis | Phase 3 | Recruiting | Alfasigma S.p.A. | 80 | 2025-09-29 | 2026-10-20 |
| A Clinical Trial of Anaprazole for Treating Reflux Esophagitis. Anaprazole + Rabeprazole placebo, Rabeprazole + Anaprazole placebo - Reflux Esophagitis (RE) | Phase 3 | Recruiting | Xuanzhu Biopharmaceutical Co., Ltd. | 500 | 2025-07-30 | 2025-09-29 |
| A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis Risankizumab - Ulcerative Colitis | Phase 3 | Recruiting | AbbVie | 120 | 2025-07-28 | 2026-10-27 |
| Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis Probiotics 6600, Placebo - Colitis, IBD (Inflammatory Bowel Disease) | Phase 2 / Phase 3 | Recruiting | Changhai Hospital | 120 | 2025-07-01 | 2025-07-02 |
Showing 20 of 51. Sign in to see all of them.
Crohn Disease (26) · Colitis, Ulcerative (19) · Inflammatory Bowel Diseases (7) · Colitis (4) · Esophagitis, Peptic (2) · Obesity (2) · Overweight (2) · Abdomen, Acute (1) · Abdominal Pain (1) · Acute Pain (1) · Appendicitis (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Carcinoma, Non-Small-Cell Lung (1) · Clostridium Infections (1)
Digestive System Diseases (51) · Gastrointestinal Diseases (51) · Intestinal Diseases (47) · Inflammatory Bowel Diseases (33) · Colonic Diseases (22) · Colitis (18) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Esophageal Diseases (3) · Esophagitis (3) · Infections (3) · Signs and Symptoms, Digestive (3) · Stomach Diseases (3) · Bacterial Infections (2)
vedolizumab (7) · guselkumab (6) · mirikizumab (4) · risankizumab (4) · Fecal Microbiota Transplantation (2) · Infliximab (2) · Saline Solution (2) · Tirzepatide (2) · Blood Specimen Collection (1) · CT-P13 (1) · Esomeprazole (1) · Fidaxomicin (1) · Fluconazole (1) · Folic Acid (1) · GLPG0634 (1)
Janssen Research & Development, LLC (7) · Takeda (7) · Eli Lilly and Company (4) · Sanofi (4) · AbbVie (2) · Assistance Publique - Hôpitaux de Paris (2) · Merck Sharp & Dohme LLC (2) · AHS Cancer Control Alberta (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Alfasigma S.p.A. (1) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire, Amiens (1) · Changhai Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · Guangzhou First People's Hospital (1)
United States (30) · Poland (28) · Belgium (26) · Canada (26) · Italy (26) · Spain (25) · France (23) · United Kingdom (23) · China (22) · Netherlands (22) · Germany (21) · Israel (20) · Japan (20) · South Korea (20) · Czechia (19)
Christina H. Ruhlmann, PhD (1) · Dr. G D'Haens, Phd MD (1) · Emily McDonald, MD MSc (1) · Franck Ruemmele, MD, PhD (1) · Huai Liu, M.D. (1)
PMID 15234753, PMID 22228948, PMID 28400848, PMID 31784469, PMID 32936964, PMID 38531570, PMID 41403476
2023 (10), 2025 (6), 2019 (1), R01DK132408 (1)